Therefore, FDA‐approved combinations of drugs that target both Raf1 and Pkm2, such as sorafenib and benserazide, may be promising for clinical liver cancer treatment, as confirmed by our combination treatment in multiple hepatocellular carcinoma cells. The gene discussed is PKM; the disease is hepatocellular carcinoma.